PL4051249T3 - Kompozycja farmaceutyczna zawierająca mitotan do podawania doustnego do leczenia raka kory nadnerczy oraz zespołu Cushing’a - Google Patents
Kompozycja farmaceutyczna zawierająca mitotan do podawania doustnego do leczenia raka kory nadnerczy oraz zespołu Cushing’aInfo
- Publication number
- PL4051249T3 PL4051249T3 PL20786346.5T PL20786346T PL4051249T3 PL 4051249 T3 PL4051249 T3 PL 4051249T3 PL 20786346 T PL20786346 T PL 20786346T PL 4051249 T3 PL4051249 T3 PL 4051249T3
- Authority
- PL
- Poland
- Prior art keywords
- cushing
- mitotane
- syndrome
- treatment
- pharmaceutical composition
- Prior art date
Links
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 title 1
- 208000014311 Cushing syndrome Diseases 0.000 title 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 title 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 title 1
- 229960000350 mitotane Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1912084A FR3102356B1 (fr) | 2019-10-28 | 2019-10-28 | Composition pharmaceutique comprenant le mitotane pour une administration par voie orale pour le traitement du carcinome corticosurrenalien et du syndrome de cushing |
| PCT/IB2020/059218 WO2021084345A1 (fr) | 2019-10-28 | 2020-10-01 | Composition pharmaceutique comprenant le mitotane pour une administration par voie orale pour le traitement du carcinome corticosurrenalien et du syndrome de cushing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL4051249T3 true PL4051249T3 (pl) | 2024-04-08 |
| PL4051249T4 PL4051249T4 (pl) | 2024-04-08 |
Family
ID=69810998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20786346.5T PL4051249T4 (pl) | 2019-10-28 | 2020-10-01 | Kompozycja farmaceutyczna zawierająca mitotan do podawania doustnego do leczenia raka kory nadnerczy oraz zespołu Cushing’a |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240058277A1 (pl) |
| EP (1) | EP4051249B1 (pl) |
| JP (1) | JP2023500494A (pl) |
| KR (1) | KR20220088904A (pl) |
| CN (1) | CN114599347A (pl) |
| AU (1) | AU2020377140A1 (pl) |
| CA (1) | CA3153794A1 (pl) |
| ES (1) | ES2966481T3 (pl) |
| FR (1) | FR3102356B1 (pl) |
| HR (1) | HRP20231641T1 (pl) |
| HU (1) | HUE064738T2 (pl) |
| MX (1) | MX2022004255A (pl) |
| PL (1) | PL4051249T4 (pl) |
| RS (1) | RS64962B1 (pl) |
| WO (1) | WO2021084345A1 (pl) |
| ZA (1) | ZA202205923B (pl) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4146648A (en) * | 1977-07-14 | 1979-03-27 | Bristol-Myers Company | Chemotherapeutic composition |
| IL101007A (en) * | 1992-02-18 | 1997-08-14 | Pharmos Ltd | Dry stable compositions prepared by lyophilization |
| CN101410098B (zh) * | 2006-01-23 | 2012-01-18 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 包括含亲脂性药物的纳米胶囊的微球 |
| EP2255786A1 (en) | 2009-05-25 | 2010-12-01 | HRA Pharma LLC | Self-microemulsifying mitotane composition |
| US20130317117A1 (en) | 2010-11-24 | 2013-11-28 | Pharmaceutics International, Inc. | Self micro-emulsifying drug delivery system with increased bioavailability |
| CN105250221B (zh) * | 2014-07-14 | 2018-06-19 | 天津药物研究院 | 一种利可瑞特干乳剂及其制备方法 |
-
2019
- 2019-10-28 FR FR1912084A patent/FR3102356B1/fr active Active
-
2020
- 2020-10-01 HR HRP20231641TT patent/HRP20231641T1/hr unknown
- 2020-10-01 CA CA3153794A patent/CA3153794A1/en active Pending
- 2020-10-01 AU AU2020377140A patent/AU2020377140A1/en active Pending
- 2020-10-01 CN CN202080074567.7A patent/CN114599347A/zh active Pending
- 2020-10-01 MX MX2022004255A patent/MX2022004255A/es unknown
- 2020-10-01 US US17/639,578 patent/US20240058277A1/en active Pending
- 2020-10-01 KR KR1020227017439A patent/KR20220088904A/ko unknown
- 2020-10-01 PL PL20786346.5T patent/PL4051249T4/pl unknown
- 2020-10-01 ES ES20786346T patent/ES2966481T3/es active Active
- 2020-10-01 HU HUE20786346A patent/HUE064738T2/hu unknown
- 2020-10-01 RS RS20231201A patent/RS64962B1/sr unknown
- 2020-10-01 JP JP2022525536A patent/JP2023500494A/ja active Pending
- 2020-10-01 EP EP20786346.5A patent/EP4051249B1/fr active Active
- 2020-10-01 WO PCT/IB2020/059218 patent/WO2021084345A1/fr active Application Filing
-
2022
- 2022-05-27 ZA ZA2022/05923A patent/ZA202205923B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020377140A1 (en) | 2022-06-09 |
| CN114599347A (zh) | 2022-06-07 |
| JP2023500494A (ja) | 2023-01-06 |
| MX2022004255A (es) | 2022-05-06 |
| CA3153794A1 (en) | 2021-05-06 |
| WO2021084345A1 (fr) | 2021-05-06 |
| HRP20231641T1 (hr) | 2024-03-15 |
| ZA202205923B (en) | 2023-04-26 |
| HUE064738T2 (hu) | 2024-04-28 |
| RS64962B1 (sr) | 2024-01-31 |
| EP4051249C0 (fr) | 2023-09-13 |
| EP4051249A1 (fr) | 2022-09-07 |
| FR3102356A1 (fr) | 2021-04-30 |
| KR20220088904A (ko) | 2022-06-28 |
| US20240058277A1 (en) | 2024-02-22 |
| FR3102356B1 (fr) | 2021-09-17 |
| ES2966481T3 (es) | 2024-04-22 |
| EP4051249B1 (fr) | 2023-09-13 |
| PL4051249T4 (pl) | 2024-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL270812B1 (en) | Solid preparations for oral administration containing semaglutide and dapagliflozin and their use in medicine | |
| IL266623A (en) | A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer | |
| WO2015160975A3 (en) | Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| LT3773615T (lt) | Skysta preparatas, skirtas vartoti burnos, gerklės, ryklės ir stemplės gleivinės gydymui | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| GB201910294D0 (en) | Liquid pharmaceutical composition for oral administration comprising paracetamol and codeine phosphate | |
| EP3753579A4 (en) | ANTI-TRAILR2 ANTIBODY TOXIN CONJUGATE AND ITS PHARMACEUTICAL USES IN ANTITUM ORTHERAPY | |
| HUE064738T2 (hu) | Orális adagolású mitotánt tartalmazó gyógyászati készítmény mellékvesekéreg karcinóma és Cushing-szindróma kezelésében történõ alkalmazásra | |
| IL285073A (en) | Concentrated liquid pharmaceutical preparations of furosemide and methods of administering these preparations | |
| IL249860A0 (en) | Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer | |
| IL271013B (en) | Allosteric egfr inhibitors with a modified isoindole, pharmaceutical preparations containing them and their use in medical treatment and/or preventive treatment of cancer | |
| EP3838270A4 (en) | SYNERGISTIC PHARMACEUTICAL COMPOSITION WITH ACECLOFENAC AND BETAMETHASONE FOR THE TREATMENT OF PAIN IN LOCALIZED FORMS OF RHEUMATIC DISEASES | |
| EP3474840A4 (en) | USE OF CYANOGLUCOSIDES AND PHARMACEUTICAL FORMULATIONS THEREOF IN THE TREATMENT OF DIABETES | |
| EP3458031A4 (en) | TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF CELECOXIB AND THEIR USE IN THE TREATMENT OF CELCOXIB-SENSITIVE DISEASES AND CONDITIONS | |
| GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases | |
| PL3768246T3 (pl) | Kompozycje farmaceutyczne sapozyny c i ich zastosowanie w leczeniu nowotworu | |
| EP4084783A4 (en) | PHARMACEUTICAL SOLUTION THAT FACILITATES DENTAL REMINERALIZATION AND ELIMINATES LESION PAIN | |
| PL3813843T3 (pl) | Kompozycja do stosowania w zapobieganiu i/lub leczeniu chorób układu kostno-stawowego | |
| TWI843751B (zh) | 適用於關節遞送的藥學組成物及其在治療關節疼痛上的用途 | |
| EP4005574A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF L-DOPA-INDUCED DYSKINESIA | |
| EP3594224A4 (en) | CELL AUTOPHAGIA SUPPRESSION COMPOSITION AND PHARMACEUTICAL COMPOSITION, INCLUDING THE SAME, FOR PREVENTION OR TREATMENT OF NEOPLASTIC DISEASES OR SUPPRESSION OF ANTI-CANCER DRUG RESISTANCE | |
| GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases |